With $44M and Microsoft R&D alliance, Volastra takes aim at metastatic cancers

Many of the cancer drugs in development are targeted therapies that address a particular genetic signature. While those drugs can treat the tumors at their origin, they aren’t much help when cancer metastasizes, or spreads. Yet it’s metastasis that is responsible for the vast majority of cancer deaths. Volastra Therapeutics aims to stop cancer metastasis. The New York-based startup has discovered a pathway that drives metastasis.
Read more...

;